NEW YORK (GenomeWeb News) – Genomic Health today announced it has attained Medicare coverage for its Oncotype Dx colon cancer test.
Palmetto GBA, the designated national contractor for the test, has created a formal coverage policy for all Medicare recipients with stage II colon cancer. The policy is effective for all claims for services performed on or after Sept. 18, the Redwood City, Calif.-based genomics testing service firm said.
Palmetto made its decision based on two large QUASAR and Cancer and Leukemia Group B clinical validation studies and additional clinical utility information.
As of June 30, more than 10,000 doctors in more than 60 countries had ordered more than 200,000 Oncotype Dx colon cancer and breast cancer tests, Genomic Health said.